This page provides an independent statistical analysis and educational interpretation of publicly reported results. It separates registered trial design from statistical interpretation. The ClinicalTrials.gov record provides the official trial registry record: NCT07190209.
1. Trial at a Glance
PERSEPHONE is a randomized, quadruple-masked, parallel-design phase 3 treatment study evaluating lunsekimig versus placebo in adults with inadequately controlled chronic obstructive pulmonary disease characterized by an eosinophilic phenotype.
| Feature | PERSEPHONE |
|---|---|
| Phase | Phase 3 |
| Condition | Chronic Obstructive Pulmonary Disease |
| Design | Randomized, parallel, quadruple-masked |
| Primary purpose | Treatment |
| Enrollment | 942 |
| Interventions | Lunsekimig and placebo |
| Lead sponsor | Sanofi |
| Study status | RECRUITING |
2. Clinical Question
The central question is whether lunsekimig provides a measurable difference compared with placebo in adults with inadequately controlled chronic obstructive pulmonary disease characterized by an eosinophilic phenotype.
Population
Adult participants with inadequately controlled chronic obstructive pulmonary disease characterized by an eosinophilic phenotype.
Intervention
Lunsekimig.
Comparator
Placebo.
Primary question
Does lunsekimig affect the annualized rate of moderate-to-severe COPD exacerbations compared with placebo?
3. Trial Design
4. Primary Endpoint
| Endpoint | Time frame | Description |
|---|---|---|
| Annualized rate of moderate-to-severe chronic obstructive pulmonary disease (COPD) exacerbations | From Baseline up to 48 weeks | The annualized moderate or severe COPD exacerbation rate up to 48 weeks treatment period compared to placebo |
5. Statistical Methodology
The primary endpoint is an exacerbation rate over a defined treatment period. Rate-based clinical trial endpoints are generally analyzed using statistical models that account for the number of events observed during follow-up and the amount of time each participant contributes to the analysis.
For an endpoint such as annualized moderate-to-severe COPD exacerbation rate, commonly used approaches include count-data models such as negative binomial regression, particularly when event counts show greater variability than expected under a simple Poisson model. These approaches can compare event rates between randomized groups while accounting for different follow-up durations.
An annualized event rate expresses the frequency of events relative to the observation period, allowing participants with different follow-up times to contribute appropriately.
6. Planned Analysis
The registry identifies the primary efficacy measure as the annualized rate of moderate-to-severe COPD exacerbations from baseline up to 48 weeks. This type of endpoint is typically analyzed using an event-rate model comparing treatment groups over the follow-up period.
The ClinicalTrials.gov record does not report posted statistical analyses or trial results for this endpoint.
7. Statistical Methods Explained
Why analyze exacerbation rate instead of only counting participants with events?
A rate-based endpoint incorporates both the number of exacerbations and the duration of observation. This allows the analysis to reflect repeated events occurring during follow-up rather than only whether a participant experienced at least one event.
What does an annualized rate measure?
An annualized rate describes the expected frequency of events standardized to a one-year period. It is a measure of event occurrence over time, not the probability that a particular participant will experience an event.
Why might a negative binomial model be used for COPD exacerbations?
COPD exacerbation counts often vary substantially between participants. A negative binomial model can accommodate extra variability in event counts that may not be captured by a simpler Poisson model.
Why is randomization important for this endpoint?
Randomization helps balance known and unknown factors between treatment groups. This supports a causal comparison of exacerbation rates between lunsekimig and placebo groups.
What does masking contribute to the trial design?
Quadruple masking reduces the potential influence of expectations from participants, investigators, care providers, and outcome assessors on trial conduct and assessment.
Why are confidence intervals important?
A confidence interval describes uncertainty around an estimated treatment effect. It provides information about precision beyond whether a statistical test crosses a significance threshold.
8. Limitations and Interpretation Issues
- No posted results: The registry does not currently report efficacy estimates, confidence intervals, p-values, or safety summaries.
- Event-rate complexity: Recurrent exacerbation endpoints require methods that account for multiple events and differing observation times.
- Follow-up period: The primary endpoint is defined through 48 weeks, so interpretation will depend on the eventual analysis population and follow-up completeness.
- Generalizability: Trial eligibility criteria and the requirement for an eosinophilic phenotype determine the population represented by the study.
- Multiple arms: A three-arm randomized structure requires appropriate comparisons and statistical planning for interpretation of treatment differences.
9. Why This Trial Matters Statistically
PERSEPHONE illustrates several important principles in modern respiratory clinical trials: randomized treatment comparison, masked assessment, recurrent-event analysis, and the use of event rates as efficacy outcomes.
| Concept | How it appears in PERSEPHONE |
|---|---|
| Randomization | Participants are assigned in a randomized study design. |
| Masking | Quadruple masking is used. |
| Parallel design | Multiple treatment arms are compared concurrently. |
| Event-rate analysis | The primary endpoint measures annualized COPD exacerbation rate. |
| Follow-up window | The primary endpoint timeframe is from baseline up to 48 weeks. |
| Registry-based reporting | ClinicalTrials.gov provides design information while results remain unposted. |
10. Sources
- ClinicalTrials.gov: NCT07190209.
Continue through the Clinical Biostats knowledge graph
Explore additional clinical trial methodology, statistical tutorials, and analytical tools.
11. Record Summary
PERSEPHONE is a phase 3 randomized, quadruple-masked, parallel study evaluating lunsekimig compared with placebo in adults with inadequately controlled chronic obstructive pulmonary disease characterized by an eosinophilic phenotype. The primary statistical focus is the annualized rate of moderate-to-severe COPD exacerbations from baseline up to 48 weeks. As the registry currently reports no posted statistical analyses or results, interpretation remains focused on the trial design and planned endpoint framework.